Univercells Unveils Innovative scale-X™ nexo Bioreactor

Univercells Technologies by Donaldson has unveiled the scale-X™ nexo bioreactor, a highly innovative miniaturized fixed-bed bioreactor that offers a 0.5 m² growth surface, making it ideal for efficient cell culture process development across various modalities. As the smallest in the scale-X family, it ensures consistent cell distribution and high density, paving the way for scalable biomanufacturing. Designed for direct scalability, it can easily transition to larger systems like the scale-X carbo (10-30 m²) and nitro (200-600 m²), offering biopharma companies a cost-effective solution to move from lab to commercial production.

The scale-X nexo bioreactor is engineered to minimize media and reagent consumption, reducing seed train efforts and lowering costs by up to 60% compared to other entry-level bioreactors. It’s equipped with ready-to-use manifolds, allowing for rapid setup and precise screening of process conditions. This makes it highly adaptable for use in a variety of applications, including cell and gene therapies and vaccines. Moreover, its integration with Skaia™ vision application software provides real-time cell number estimates without direct sampling, further enhancing operational efficiency and productivity.